| Previous Close | 13.00 |
| Open | 13.40 |
| Bid | 10.60 x 800 |
| Ask | 14.60 x 900 |
| Day's Range | 12.52 - 13.49 |
| 52 Week Range | 9.30 - 15.79 |
| Volume | 27,393 |
| Avg. Volume | 197,675 |
| Market Cap | 727.523M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Mar 30, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.34 |
-The clinical study will explore the potential of TJM2, an anti-GM-CSF monoclonal antibody, to treat cytokine release syndrome in severe and critically ill patients with.
- Kalbe Genexine Biologics (“KG Bio”) will receive right of first negotiation for an exclusive license to potentially commercialize I-Mab’s TJD5, in Southeast Asia and other.
I-Mab (the “Company”) (IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, today announced the appointment of Fernando J. Sallés, Ph.D., CLP®, as Senior Vice President, Head of U.S. & EU Business Development, effective March 30, 2020. In this newly created role, Dr. Sallés will initially be responsible for leading global out-licensing efforts and concluding global co-development partnerships/strategic alliances with large pharma and biotech companies in the United States and EU, helping to expedite the development and market entry of the Company’s products.
I-Mab (the “Company”) (IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, today announced the appointment of Gigi Feng as Vice President, Global Head of Corporate Communications, effective April 20th, 2020. Reporting to I-Mab’s Board of Directors, Feng will oversee all communications across I-Mab, partnering with the executive team to communicate the Company’s strategic narrative, R&D innovation, external collaborations and more.
-The clinical study will explore the potential of TJM2, a proprietary mAb against GM-CSF, to fight "cytokine storm” during severe COVID-19 disease -The study to be conducted.
SHANGHAI, China and ROCKVILLE, MD., March 11, 2020 -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development.
SHANGHAI, China and ROCKVILLE, MD., Feb. 25, 2020 -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development.
SHANGHAI, China and ROCKVILLE, MD., Feb. 10, 2020 -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development.
SHANGHAI, China and ROCKVILLE, Md., Jan. 17, 2020 -- I-Mab (“I-Mab” or the “Company”) (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery,.